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Abstract: Reported is an enantiodivergent approach for the synthesis of both enantiomers 
of sulforaphane (SFN) homologues with different chain length between the sulfinyl sulfur 
and the isothiocyanate groups and different substituents on the sulfinyl sulfur. The 
homologues were designed in order to unravel the effect of all the diversity elements 
included in sulforaphane’s structure. The key step of the approach is the diatereoselective 
synthesis of both sulfinate ester epimers at sulfur, using as single chiral auxiliary the sugar 
derived diacetone-D-glucose. The approach allows the first synthesis of both enantiomers 
of 5-methylsulfinylpentyl isothiocyanate, and the biologically important 6-
methylsulfinylhexyl isothiocyanate (6-HITC) found in Japanese horseradish, wasabi 
(Wasabia japonica). The ability of the synthesized compounds as inductors of phase II 
detoxifying enzymes has been studied by determining their ability to activate the 
cytoprotective transcription factor Nrf2. The cytotoxic activity of all the synthesized 
compounds against human lung adenocarcinoma (A549) and embryonic lung fibroblasts 
(MRC-5) is also reported.  
 
 
Keywords: (R)- and (S)-Sulforaphane and Homologues; Enantiodivergent synthesis, 
Activation of Nrf2 factor; cytotoxic activity, DAG-methodology. 
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1. Introduction. 
 In the last years, there are more and more evidences that support the intimate 
relationship between nutrition and health [1]. This relationship was already known 
from classical Greece, when Hippokrates, 500 BC, recommended "Let your food be 
your medicine, and your medicine be your food". Centuries later Cervantes in Don 
Quixote argued that "the health of the whole body is forged in the office of the 
stomach". Re-awareness in modern medical science on the importance of certain 
foods to maintain health, prevent and alleviate diseases has induced an explosion of 
research on dietary phytochemicals and brought up new concepts and terminologies 
[2,3]. Among the star foods, cruciferous vegetables, rather than vegetables as a 
group, have drawn a great deal of attention because of their excellent activities in 
cancer prevention [4]. 
 In this sense, epidemiological and clinical studies have established that 
populations with a diet rich of broccoli and other cruciferous vegetables, such as 
cauliflower, watercress, Brussels sprouts, and cabbage are less prone to develop 
certain types of cancers as well as some chronic degenerative diseases [5].
 
Compelling evidences indicate that the chemical carcinogenesis prevention and 
chemotherapeutic benefit of cruciferous are attributable to their high contents of 
phytochemicals containing an isothiocyanate functional group [6]. These organic 
isothiocyanates are not produced as such by the plant, but they result from the 
enzymatic action of the thioglycosidase myrosinase on natural glucosinolates ( -
thioglucoside-N-hydroxysulfates), such as glucopharin 1, Scheme 1 [7].  
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Scheme 1. Biosynthetic pathway to (RS)-sulforaphane 2 and (RS, SC)-sulforaphane-cysteine 
analogue 3: Lossen rearrangement through myrosinase deglycosylation of glycopharin 1 
followed by mercapturic acid pathway. 
 
Myrosinase is released from intracellular vesicles following mechanical damage to 
the plant tissue, such as that caused by chewing, food preparation, or damage by 
insects.
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 Myrosinase catalyses the hydrolysis of the thioglycosidic bond leading to 
unstable intermediates, which at physiological pH, predominantly undergo Lossen 
rearrangements to the corresponding isothiocyanate, such as 2 [9]. (RS)-1-
isothiocyanato-4-(methylsulfinyl)-butane (sulforaphane 2), firstly isolated in 1992 
from broccoli extracts [10], is the main inducer of phase II detoxifying enzymes and 
is well documented as a powerful chemopreventive agent [11]. In this regard, animal 
studies on rats have established the chemopreventive activity of sulforaphane against 
colon cancer [12], and recent preclinical and clinical studies have confirmed the 
chemopreventive activity of sulforaphane in women at risk for breast cancer [13]. In 
addition to increasing cellular capacity for detoxifying electrophiles and oxidants, 
SFN has been shown to induce apoptosis, and to inhibit cell cycle progression and 
angiogenesis [14-19]. Most recently, SFN has also been shown to induce anti-
proliferative effects via epigenetic mechanisms [20], namely acting as dietary 
histone deacetylase inhibitor through its metabolite SFN-cysteine 3 [21, 22], and to 
suppress DNA methylation [23].
 
7 
 
In nature, besides the common glycone moiety, the glycosinolate molecules possess a 
variable side chain derived from amino acids [24], which in the case of sulforaphane is 
characterized by the presence of a methylsulfinyl group. The presence of the sulfinyl group 
is not limited to SFN, but has been described for other isothiocyanates such as iberin (1-
isothiocyanato-3-(methylsulfinyl)-propane) [25], 1-isothiocyanato-6-(methylsulfinyl)-
hexane (6-HITC) [26], 1-isothiocyanato-7-(methylsulfinyl)-heptane (7-HITC), and 1-
isothiocyanato-8-(methylsulfinyl)-octane (8-OITC) [27]. Among these homologues 6-
HITC, found in Japanese horseradish, wasabi (Wasabia japonica, syn. Eutrema wasabi), is 
rapidly absorbed by the body and induces hepatic phase II detoxification enzymes more 
potently than SFN. Based on these results, in the last years there has been an intense 
research for the determination of the relation structure-activity of SFN, with the aim of 
finding biologically more active and chemically more stable analogues [28-32]. These 
researches were dedicated primarily to the simplification of SFN structure by using a rigid 
core between the sulfinyl sulfur and the isothiocyanate group for instance, or by eliminating 
or replacing the chiral sulfinyl group. Recently, researches were directed toward the 
modulation of the isothiocyanate reactivity, by using a less electrophilic functionality [33]. 
The data accumulated so far, indicate that the structural characteristics of natural 
isothiocyanate play a key role in their biological activities, as very small changes induce an 
important effect on the chemopreventive activities. In this regard, it has been shown that the 
oxidation state of the sulfur is important as both, the thioether and the sulfone analogues are 
less active than the corresponding sulfoxide derivatives. With regard to the sulfur chirality, 
it should be indicated that natural sulforaphane, iberin, and most probably all methyl 
sulfinyl analogues exist as a single enantiomer with an RS absolute configuration [34], as 
the oxidation of the sulfide in the gluosinolates by flavin monooxygenase has been recently 
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reported to be stereospecific [35]. Nevertheless, up to now few studies have addressed the 
sulfur chirality importance on the biological activity of SFN [36]. In this sense, while 
original data indicate that the sulfur chirality has no significant biological effect, a recent 
study shows that natural R-sulforaphane is a far more potent inducer of the carcinogen-
detoxifying enzyme systems in rat liver and lung than the unnatural  S-isomer [37]. A 
subsequent study on the modulation of glucuronosyl transferase and epoxide hydrolase, two 
major carcinogen-metabolising enzyme systems, showed that the R-enantiomer enhanced, 
whereas the S-enantiomer impaired, glucuronosyl transferase activity and that the R-
sulforaphane was more effective than the S-enantiomer in up-regulating microsomal 
epoxide hydrolase [38]. Finally, while the nature of the chain linking the electrophilic 
isothiocyanate group and the Lewis basic sulfinyl moiety on their anticancer activity has 
been determined, only few studies have been conducted on the importance of the 
substituent at the sulfinyl sulfur [31, 32, 39]. It should be noted that despite the great efforts 
made, and the hundreds of analogues assayed, no one surpassed yet the biological activity 
of natural SFN. 
Figure 1: Structure of sulforaphane and homologues synthesized in this work. 
Based on these premises, and as a part of our research program on sulforaphane 
analogues, we decided to study the effect of all the diversity elements enclosed in 
sulforaphane generic structure I (Figure 1), namely: (i) the chain length between the 
sulfinyl sulfur and the isothiocyanate group, (ii) the steric hindrance of the 
substituent at sulfur, and (iii) the sulfur stereochemistry. Therefore, herein we report 
a convergent and high yielding approximation to both isomers of sulforaphane (2RS, 
2SS) and analogues 4RS, 4SS,  5RS,  5SS,  6RS, and 7RS,  Figure 1, with different 
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substituents at the sulfinyl sulfur, varied alkyl chain length between the two 
functional groups, and in both enantiomeric forms. The biological activity of these 
compounds as inductors of phase II detoxifying enzymes has been studied by 
determining their ability to activate the cytoprotective transcription factor Nrf2. The 
anti-cancer activity has been determined by evaluating their selective cytotoxic 
effect in human lung adenocarcinoma (A549) and non-malignant lung cells (MRC-
5). 
 
2. Results and discussion 
2.1. Chemical synthesis 
 The last decade has witnessed a renewed interest towards the preparation of chiral 
sulfoxides as a consequence of their high efficiency, and wide applicability as chiral 
controllers in asymmetric carbon-carbon and carbon-heteroatom bond formation [40, 
41].
 
Additionally, besides sulforaphane, there are a number of pharmacologically 
relevant drugs [42], which have in their structure a sulfinyl group including the 
proton pump inhibitor esomeprazole [43], the vigilance promoting armodafinyl 
[44],
37
 and the anti-inflammatory sulindac [45].  
Although the natural sulforaphane exists as a single enantiomer in nature, most 
studies conducted on its biological activities have been conducted using the racemic 
form. As an alkyl methyl sulfoxide, the synthesis of enantiopure sulforaphane is not 
straightforward [46-49], and the main approximations for the synthesis of 
enantiomerically pure sulfoxides developed so far fail in the preparation of simple 
dialkyl sulfoxides. Actually, there is no asymmetric catalytic oxidation able to give 
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enantiomerically pure dialkyl sulfoxides from the corresponding prochiral thioethers 
[50]. In the particular case of sulforaphane, only four approximations have been 
reported so far, two of them give the natural enatiomer in scalemic form. The first 
one, developed by Holland’s group, used a microbial oxidation with 
Helmithosporium sp of the corresponding prochiral sulfide, which afforded RS-
sulforaphane in 86% ee and 54% yield [51]. Whitesell’s group used trans-2-phenyl 
hexanol as chiral auxiliary for the synthesis of diasteromerically pure methyl 
sulfinate ester 8, from which RS-sulforaphane was obtained through 5 steps and 42% 
overall yield [52]. Schenk’s group employed a method based on a diastereoselective 
oxidation of cationic ruthenium complex 9, which leads to RS-sulforaphane with a 
good 80% ee [53].
 
 
Figure 2: Diastereomeric intermediates used for the synthesis of enantiopure and 
scalemic RS-sulforaphane 
 
 Noteworthy, none of these methods is able to give sulforaphane analogues with 
substituent at the sulfur different from a methyl group. In order to solve this problem 
we have recently reported that sulfinate ester 10, is an effective sulfinylating agent 
able to efficiently transfer the linear alkyl sulforaphane side chain in enantiomeric 
form [39]. In the present work, in order to modulate the different variables of 
sulforaphane, we need a methodology capable of producing sulforaphane 
homologues with different substituents at the sulfur, and different chain length 
between the sulfoxide and the isothiocyanate groups, preferably in both enantiomeric 
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forms. In this regard, the “DAG-methodology” [54], developed in our group, seems 
the method of choice as it is able to give a diasteromerically pure sulfinate ester with 
a non-hindered alkyl chain at the sulfinyl sulfur. Additionally, based on our 
experimental and theoretical studies [55], both epimers at sulfur should be accessible 
in an enantiodivergent manner, by a simple change of the base used to catalyse the 
reaction, from the corresponding  sulfinyl chlorides [56].  
For the synthesis of the desired 1-azidobutanesulfinyl chloride, 1-
azidopentanesulfinyl chloride, and 1-azidohexanesulfinyl chloride, two approaches 
were used, starting either from the corresponding chloro-alcohols 11, 13 or from the 
diol 12, Scheme 2.  
 
Scheme 2: Synthesis of 1-azido-butanesulfinyl chlorides 23-25. a) NaN3, DMF, b) 
MsCl, NEt3, CH2Cl2, c) KSAc, DMF, d) SO2Cl2, Ac2O, CH2Cl2.  
 
 Treatment of 1-chlorobutanol 11 or 1-chlorohexanol 13 with sodium azide in 
DMF afforded the azido alcohols 14 and 16 in 73% and 98% yields respectively, 
which after mesylation gave the azido mesylate intermediates 17 and 19 in excellent 
yields. Alternatively, a double mesylation of 1,5-pentanediol 12, afforded the 
dimesylated compound 15, which was de-symmetrized to give compound 18 by 
reaction with sodium azide in DMF. Treatment of the mesylates 17, 18 and 19 with 
sodium thioacetate afforded compounds 20, 21 and 22 in 84%, 82% and 85% yields, 
respectively. The direct transformation of thioacetates 20-22 to the desired sulfinyl 
chlorides 23, 24 and 25 has been achieved by treatment with sulfuryl chloride and 
acetic anhydride in methylene chloride [57]. 
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Once the sulfinyl chlorides in hand, we conducted the diastereodivergent syntheses 
of the corresponding DAG sulfinate esters using our “DAG methodology”. In this 
methodology, a single inducer of chirality, Diacetone-D-glucose (DAG), is used for 
the stereoselective synthesis of both diastereomerically pure (R)- and (S)-sulfinate 
esters, by dynamic kinetic resolution of the corresponding sulfinyl chloride, thanks 
to the opposite stereodirecting effect of the base used to catalyze the reaction [51]. In 
this sense, using Hunig-base, (SS)-DAG sulfinate esters are generally obtained in 
good to high chemical yields and d.e’s, while the use of pyridine as base afforded the 
epimers at sufur (RS)-DAG sulfinate esters. Theoretical studies at the ONIOM 
(Beckel3LYP:UFF) level, reproduced the experimental results and showed that the 
base used plays a dual role, catalyzing the interconversion of both enantiomers of 
sulfinyl chlorides, and assisting the displacement of the chlorine by DAGOH. The 
analysis of the optimized geometries revealed that the most sterically relevant 
substituent around the sulfur is the R group of the substrate with pyridine as base, 
but the base itself with DIPEA. This leads to an inversion of the chiral distribution of 
steric hindrance around sulfur that induces the reversal of the stereochemical 
outcome and the enantiodivergency observed [54].
  
 
Scheme 3: Enantiodivergent synthesis of (S)- and (R)-sulfinate esters 10, 26, and  27 
using the DAG-methodology 
  
 In accord with the theoretical studies, the treatment of DAG with 
azidoalcanesulfinyl chlorides 23, 24  and 25, in the presence of DIPEA afforded the 
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(S)- sulfinate esters 10-SS, 26-SS , and 27-SS, with 92%, 92% and 87% yields and a 
good 94%, 88% and 84% de’s; although lower than that obtained with other sulfinyl 
chlorides, which are usually obtained as a single diastereoisomer.  Interestingly, 
when pyridine was used as base, (R)-sulfinate esters 10-RS, 26-RS, and 27-RS, were 
predominantly obtained in 90%, 87%, and 86% yields respectively, although in a 
lower diastereomeric excesses, Scheme 3. The diastereoselectivity of all the 
reactions has been easily determined by 
1
HNMR analysis of the crude, employing 
deuterated benzene as solvent. In all sulfinates esters, the use of C6D6 induces a 
splitting of the anomeric protons, as well as that of the protons in the two and three 
positions of the SS-sulfinate esters and their epimers the RS-sulfinates (see supporting 
information). Additionally, all the diastereomeric sulfinate esters possess a good 
separation factor, which allows their preparation in optically pure form by column 
chromatography.  
Taking into account that the reaction of sulfinate esters with Grignard reagents takes 
place with inversion of configuration at the sulfinyl sulfur, the SS-DAG sulfinate 
esters are the intermediates, which will lead to sulforaphane and sulforaphane 
homologues with the same absolute configuration as the natural sulforaphane, while 
RS-DAG sulfinate esters will afford unnatural homologues. 
 
Scheme 4: Synthesis of enantiopure natural sulforaphane 2-RS and homologues 4-RS 
and 5-RS: a) CH3MgBr, toluene b) (i) PPh3, Et2O, reflux, (ii) CS2, reflux 
 
 In this sense, condensation of methyl Grignard on the sulfinate ester 10-SS, 26-SS 
and 27-SS afforded the corresponding azidoalkyl methyl sulfoxides 28-RS, 29-RS, and 
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30-RS in 90%, 74% and 73% yields, respectively, Scheme 4. Staudinger reaction of 
the azido derivatives with triphenylphosphine and subsequent aza Wittig-type 
condensation of the resulting iminophosphorane with carbon disulfide lead to 
enantiomerically pure natural (-)-sulforaphane 2-RS, and for the first synthesis of 
enantiopure homologues 4-RS, and 5-RS in 98%, 91% and 81% yields, respectively, 
Scheme 4. Similarly, condensation of methyl Grignard on the sulfinate ester 10-RS, 
26-RS and 27-RS afforded the corresponding 4-azidobutyl methyl sulfoxides 28-SS, 
29-SS, and 30-SS in 87%, 78% and 81% yields, respectively, Scheme 5.  After 
Staudinger reaction and subsequent aza Wittig-type condensation of the resulting 
iminophopsphorane with carbon disulfide lead to enantiomerically pure unnatural 
(+)-sulforaphane 2-SS, and for the first synthesis of the enantiopure homologues 4-
SS, and 5-SS in 78%, 97% and 87% yields respectively, Scheme 5. 
 
Scheme 5: Synthesis of enantiopure unnatural sulforaphane 2-SS and homologues 4-
SS and 5-SS: a) CH3MgBr, toluene b) (i) PPh3, Et2O, reflux, (ii) CS2, reflux 
 
 We have previously reported data, pointing out that the steric hindrance of the 
substituent at the sulfinyl sulfur may strongly affect the activation of the 
cytoprotective Nrf2 transcription factor. In order to complete these studies and to 
know to what extent we can increase the size of the sulfur substituent without 
affecting the biological activity of sulforaphane, we designed compounds 6-RS and 
7-RS with the same absolute configuration at sulfur than the natural (-)-sulforaphane, 
but having an ethyl and butyl substituent instead of a methyl group.  
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Condensation of the adequate Grignard reagent on sulfinate ester 10-SS lead to the 
desired azido sulfoxides 31 and 32. A subsequent 2-reactions-one pot sequence leads 
as before to the enantiopure sulfinyl isothiocyantes 6-RS and 7-RS in 95% and 98% 
yields respectively, Scheme 6. 
 
Scheme 6: Synthesis of enantiopure sulforaphane analogues 6-RS and 7-RS: a) 
C2H5MgBr, toluene b) C4H7MgBr, toluene, c) (i) PPh3, Et2O, reflux, (ii) CS2, reflux 
 
2.2. Biological activities of sulforaphane homologues 
2.2.1 ACTIVATION OF NRF2 
 Experimental evidences indicate that sulforaphane exerts its anti-cancerogenic 
activity through the activation of “nuclear factor erythroid derived 2, like 2” (Nrf2) 
[58]. Nrf2 is a transcription factor, which controls the expression of a battery of 
cytoprotective genes in humans and animals [59]. However, unlike many other 
transcription factors, the major path of activation is not controlled by a kinase, but by 
direct covalent modification of the Nrf2 inhibitor Keap1 by electrophilic 
compounds. Activated Nrfd2 dimerizes with small Maf proteins or other leucine 
zipper proteins and binds as a heterodimer to the antioxidant response element 
(ARE) in the promoter or enhancer of its target genes. Genes that are regulated by 
Nrf2 encode proteins that help to control the cellular redox status and protect the cell 
against oxidative damage. These include a series of enzymes that detoxify reactive 
oxygen species (ROS) and other antioxidant proteins, including NAD(P)H 
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dehydrogenase quinone 1 (NQO1), several glutathione S-transferases (GST), -
glutamylcysteine synthetase ( -GCS), peroxiredoxin 1, and heme oxygenase 1 (HO-
1) [60]. The prevailing hypothesis for sulforaphanes’s cellular mechanism is that the 
natural product covalently modifies Keap1 on one or more of its 27 cysteine 
residues, altering the Keap1-Nrf2-Cullin-3 protein complex [61]. This allows 
stabilization and accumulation of newly synthetized Nrf2 in the nucleus, where it 
can activate the expression of its target genes.  
The key step of the process is the interaction of sulforaphane with Keap1, where the 
structure of sulforaphane must play a preponderant role. In this regard, we have 
recently emitted the hypothesis that the function of the sulfinyl group, which has not 
been determined yet, must be that of optimizing the side interaction of sulforaphane 
with Keap1, probably through hydrogen bond interaction with amino acids near the 
reactive cysteines. This hypothesis is based on the fact that analogues with a 
hydrogen bond acceptor such a ketone group are as active as 2, while those lacking 
this kind of groups are less active. In accord with this hypothesis we have recently 
shown that the steric hindrance of the substituent at the sulfinyl sulfur have a 
substantial effect on the biological activity. 
 
Figure 3: Dose dependent effects of sulforaphane analogues on the activation of an 
ARE reporter gene. HaCaT keratinocytes were transiently transfected with a rat 
NQO1-ARE luciferase reporter plasmid and the phRL-CMV Renilla luciferase 
vector. Transfected cells were incubated for 24h with different concentrations of 
sulforaphane 2-RS and homologues 4-RS, 4-SS 5-RS, 5-SS, 6-RS, and 7-RS. Results 
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were normalized to the renilla luciferase activity. Values show mean +/- S.D. from 
triplicate determinations.  The result was reproduced in an independent transfection 
experiment. 
 
 
 The ability of natural sulforaphane and homologues 4-RS, 4-SS, 5-RS, 5-SS, as well 
as 6-RS, and 7-RS to activate Nrf2 was investigated by transfecting immortalized 
human keratinocytes (HaCaT cells) with a reporter construct containing a 31bp 
segment of the rat Nqo1 promoter with the core ARE (pGL3-rNQO1 ARE) [62, 63]. 
The transfected cells were treated with five different concentrations of sulforaphane 
analogues (50nM, 0.5µM, 5µM, 50µM, and 500µM), and the results are given in 
figure 3. The concentrations 50µM and 500µM were toxic for the cells (data not 
shown). At lower concentrations, however, a clear difference between the original 
sulforaphane and its analogues was identified, with all homologues, being equal or 
more active compared to the original compound. The activation of Nrf2 was 
intimately related to the length of the alkyl chain between the isothiocyanate and the 
sulfoxide group. With regard to the substituent at the sulfinyl sulfur dialkyl 
sulfoxides 6-RS and 7-RS, have the same activity as natural sulforaphane. Taking into 
account that in our previous study we have shown that analogue with a pentyl group 
at sulfur was less active than SFN; we can conclude that the largest group, which can 
replace the methyl group of sulforaphane, is a butyl group. On the one hand, if we 
consider the statistical studies, although there is no noticeable difference between the 
ARE-activating activity of different homologues and sulforaphane 2-RS, we can see 
that the increase in the length of the carbon chain separating the isothiocyanate 
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group sulfinyl sulfur from 4 to 5 to 6 carbon atoms positively influences the ARE-
activating activitiy of the homologues. Also, comparing the results obtained with 
compounds 4-RS and 5-RS, with those obtained with their enantiomers 4-SS and 5-SS, 
we can conclude that the configuration at sulfur plays no role in the activation of 
Nrf2. Therefore, the most important conclusion from the study of this family of 
homologues is that both enantiomers of 1-isothiocyanato-6-(methylsulfinyl)-hexane 
5 (6-HITC), found in Japanese horseradish, wasabi (Wasabia japonica, syn. Eutrema 
wasabi), are at least equally or even more potent than the natural sulforaphane. 
 
2.2.2. SELECTIVE CYTOTOXICITY FOR CANCER CELLS 
As already mentioned, natural (RS)-sulforaphane is not only able to prevent, but may 
also help to cure several types of cancer [14-18]. In order to test the cytotoxic 
activity for cancer cells as well as the selectivity and safety toward normal cells of 
our synthesized analogues, we have performed cytotoxicity assays. For this study, 
we used the human adenocarcinoma A549 cell line as cancer cells and fetal lung 
fibroblasts (MRC-5 cell line) as normal cells. The cell viability has been quantified 
by the colorimetric MTT assay, which measures the mitochondrial dehydrogenase 
activity [64, 65]. The cytotoxicity and selectivity of the synthetic analogues were 
quantified by determining the IC50 value of each compound for cancerous and 
normal cells, and the results are given in table 1.  As a negative control, we 
evaluated the cytotoxic activity of lactic acid (Table 1, entry 1), together with 
cisplatin, a clinically used drug as a positive control (Table 1, entry 2). 
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Table 1. Selective cytotoxic effect of sulforaphane analogues on tumoral (A549) and 
normal (MRC-5) cells 
 
 These results indicate that natural sulforaphane show some selectivity against the 
tumor cell line, as its IC50 for the healthy lung cell line is more than double than for 
the tumoural cell line (Table 1, entry 3). With regard to the effect of chain length 
between the sulfoxide and the isothiocyanate group, although no significant 
differences in cytotoxic activity of the analogues was seen when we pass from five 
(Table 1, entries 4-5) to six carbon atoms (Table 1, entries 6-7), it is important to 
note that in both cases, a decrease of the IC50 compared to sulforaphane was 
observed. These results indicate that the synthesized analogues are more effective 
against lung cancer cells than natural sulforaphane. It is precisely at concentrations 
near these IC50 (10  M) where toxicity difference of these products occurs, because 
a 50% of cell inhibition was observed for the cancer cell line, only a 20% inhibition 
was seen for the normal cells, Figure 4. The same trend was observed in the case of 
the derivative 7-RS, analogue (Table 1, entry 7) where the methylsulfinyl group was 
substituting an n-butylsulfinyl. Not only a decrease in IC50 (A549) was observed up 
to values close to 10 M, but at the same concentration, about 90% cell viability was 
maintained for the healthy lung cell line. Furthermore, the analogue 6-RS with an 
ethylsulfinyl group have an anticancer activity similar to that of sulforaphane (Table 
1, entry 8), but turns out to be somewhat less toxic to normal lung cells. Finally, 
from all tested analogues only 5-SS (Table 1, entry 7) could match the slight 
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selectivity of SFN (Table 1, entry 7) towards the cancer cells, which was 2.3-fold 
and lower than that of the anticancer agent cisplatin. 
 
Figure 4. Inverted microscope images corresponding MRC-5 and A549 cell lines 
following treatment with 5-SS analogue at a 10 M concentration  
 
3. CONCLUSIONS  
In conclusion, we have developed a convergent and highly efficient approximation 
for the synthesis of both enantiomers of sulforaphane and six of its analogues with 
different chain length between the sulfinyl sulfur and the isothiocyante group, and 
different substituents at the sulfinyl sulfur. The efficiency of the obtained 
homologues as inductors of phase II detoxifying enzymes was determined by 
studying their ability to activate the cytoprotective transcription factor Nrf2. The 
results obtained indicate from one side, that lengthening the alkyl chain between the 
sulfinyl sulfur and the isothiocyanate group from 4 to 6 carbon atoms has a 
beneficial effect on the activation of Nrf2. Conversely, increasing the steric size of 
the substituent on the sulfur has a negative effect on the biological activity, the ethyl 
being the largest group allowed to replace the methyl substituent. The identical 
results obtained with both enantiomers of the compounds tested, indicates that sulfur 
stereochemistry has no effect on the ability of these analogues to activate the 
cytoprotective transcription factor Nrf2. Cytotoxicity activity studies show that all 
tested analogues are cytotoxic for cancer cells. Relation structure activity shows that 
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as in the case of Nrf2 activation, lengthening the alkyl chain between the sulfinyl 
sulfur and the isothiocyanate has a beneficial on the cytotoxic activity, and that the 
sulfur stereochemistry has no effect. Conversely, increasing the steric size of the 
substituent on the sulfur has a positive effect on the cytotoxic activity, the analogue 
with butyl group being the most cytotoxic compound. 
 
4. Experimental Section 
General experimental methods. All reactions were run under an atmosphere of dry 
argon using oven-dried glassware and freshly distilled dried solvents. THF and 
diethyl ether were distilled from sodium benzophenone ketyl. Dichloromethane and 
toluene were distilled from calcium hydride. TLC was performed on Silica Gel 
GF254 (Merck) with detection by charring with phosphomolybdic acid/EtOH. For 
flash chromatography, silica Gel (Merck 230-400 mesh) was used. Columns were 
eluted with positive air pressure. Chromatographic eluents are given as volume to 
volume ratios (v/v). NMR spectra were recorded with a Bruker Avance DPX300 
(1H, 300 MHz) and Bruker Avance DRX500 (1H, 500 MHz) spectrometers. 
Chemical shifts are reported in ppm, and coupling constants are reported in Hz. 
Routine spectra were referenced to the residual proton or carbon signals of the 
solvent. High-resolution mass spectra were recorded on a Kratos MS-80RFA 241-
MC apparatus. The organic extracts were dried over anhydrous sodium sulfate and 
concentrated in vacuum. 
4.1. Chemistry 
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4-azidobutan-1-ol (14).  
 A suspension of 4-chlorobutanol 11 (5.1 g, 47 mmol) and sodium azide (9.16 g, 
141 mmol) in water (10 mL) were placed in a 10-20 mL crimp-sealed microwave 
vial equipped with a magnetic stirrer. The reaction tube was placed inside the cavity 
of a Biotage Initiator Mmicrowave Synthesizer, operated at 130 ºC, power 50 Watt 
and pressure 7-9 bar for 30 minutes. After completion of the reaction, the aqueous 
layer was extracted with diethyl ether twice. The resulting organic layers were 
combined, dried on Na2SO4, and concentrated under vacuum to give 3.95 g (73 %) 
of 14 as colourless oil. Rf = 0.35 (CH2Cl2/EtOAc, 92:1); 
1
H NMR (500 MHz, 
CDCl3) 3.70 (t, 2H, J = 6Hz), 3.35 (t, 2H, J = 6.5Hz), 1.72-1.67 (m, 4H), 1.54 (s, 
1H); 
13
C NMR (125 MHz, CDCl3) δ 62.2, 51.3, 29.7, 25.4.  
5-methylsulfonyloxypentyl methanesulfonate (15).  
 To a solution of 1,5-pentanediol 12 (5.66 g, 54.4 mmol) and EtN3 (16.7 mL, 119 
mmol) in THF (80 mL) at 0ºC was added dropwise methanesulfonyl  chloride (11.7 
mL, 119 mmol). After 1h at 0ºC, the reaction mixture was quenched with saturated 
NH4Cl solution and extracted with CH2Cl2 twice. Then the combined organic layers 
were dried over Na2SO4 and evaporated to dryness. The crude product was purified 
by silica gel chromatography using 1:1 Hexanes/EtAcO, affording 12.73 g (90%) of 
15 as colourless liquid. Rf = 0.50 (Hexanes/EtAcO, 1:2); 
1
H NMR (300 MHz, 
CDCl3) δ 4.23 (t, 2H, J = 6.3 Hz), 3.00 (s, 3H), 1.84-1.75 (m, 4H), 1.64-1.52 (m, 
2H); 
13
C NMR (75 MHz, CDCl3) δ 69.5, 37.4, 28.5, 21.6; HRMS (FAB) calcd. or 
C7H17N3O6S2 (M+Na)
+
: m/e 261.0467, found m/e 261.0465. 
6-azidohexan-1-ol (16). 
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To a solution of 6-chlorohexan-1-ol 13 (15 g, 109.80 mmol) in dry DMF (50 mL) 
was added sodium azide (22.83 g, 351.36 mmol) and 18-crown(6) (0.77 mmol) . The 
reaction mixture was heated to 70 ºC overnight. The NaN3 was filtered and the 
solvent was removed by vacuum. The residue was resuspended in water and 
extracted with Et2O twice. The organic layer was dried over anhydrous Na2SO4, and 
the solvent was evaporated to afford 15.4 g (98% yield) of 16 as colourless oil, 
which was used without further purification. An analytical sample was purified by 
column chromatography (silica gel) for characterization employing 7:3 
CH2Cl2/Hexanes as eluent. Rf = 0.35 (CH2Cl2); 
1
H NMR (300 MHz, CDCl3) 3.63 (t, 
2H, J = 6.5 Hz), 3.26 (t, 2H, J = 6.9 Hz), 1.65-1.52 (m, 4H), 1.50 (sa, 1H), 1.42-1.37 
(m, 4H); 
13
C NMR (75 MHz, CDCl3) δ 62.7, 51.3, 32.5, 28.7, 26.5, 25.3; HRMS 
(FAB) calcd. for C6H13N3O (M)
+
 m/e 143.1059, found m/e 143.1059. 
Synthesis of azidoalkyl methanesulfonate 17 and 19  from azidoalkylalcochols. 
General Procedure. 
 To a solution of the azidoalkylalcohol and triethylamine (110 mol%) in methylene 
chloride, at 0 ºC, was added methanesulfonyl chloride (110 mol%) dropwise. After 
1.5 h at 0ºC, the reaction mixture was quenched with saturated NH4Cl aqueous 
solution and extracted with CH2Cl2 twice. Then the combined organic layers were 
dried over anhydrous Na2SO4 and evaporated to dryness. The residue was purified 
by flash chromatography to give the desired product. 
4-azidobutyl methanesulfonate (17). It was prepared following the general 
procedure from 4-azidobutan-1-ol 14 (3.95 g, 34.3 mmol). Purified by Flash 
Chromatography (2:1, CH2Cl2/Hexanes) gave 4.76 g (72% yield) of 17 as colourless 
oil. Rf = 0.54 (EtOAc/ Hexanes, 1:2); 
1
H NMR (300 MHz, CDCl3) δ 4.27 (t, 2H, J = 
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6.3Hz), 3.36 (t, 2H, J = 6.6Hz), 3.02 (s, 3H), 1.91-1.72 (m, 4H); 
13
C NMR (75 MHz, 
CDCl3) δ 69.12, 50.74, 37.44, 26.47, 25.05. 
6-azidohexyl methanesulfonate (19). It was prepared following the general 
procedure from 6-azido-hexan-1-ol 16 (15.4 g, 107.7 mmol). Purified by Flash 
Chromatography (4:1, CH2Cl2/Hexanes) gave 23.4 g (98% yield) of 19 as colourless 
oil. Rf = 0.25 (CH2Cl2/Hexanes, 4:1); 
1
H NMR (300 MHz, CDCl3) δ 4.22 (t, 2H, J = 
6.4 Hz), 3.27 (t, 2H, J = 6.8 Hz), 3.00 (s, 3H), 1.81-1.72 (m, 2H), 1.66-1.55 (m, 2H), 
1.50-1.37 (m, 2H); 
13
C NMR (75 MHz, CDCl3) δ 69.7, 51.2, 37.3, 28.9, 28.6, 26.1, 
25.0; HRMS (FAB) calcd. for C7H15N3O3NaS (M+Na)
+
: m/e 244.0732, found m/e 
244.0737. 
5-azidopentyl methanesulfonate (18). To a solution of  dimesylate 15 (12.6 g, 48 
mmol) in DMF (100 mL) was added sodium azide (3.14 g, 48 mmol). The reaction 
mixture was heated to 70 ºC for 90 min, then cooled to room temperature and diluted 
with Et2O. The organic layer was washed with H2O and brine, dried over anhydrous 
Na2SO4, and concentrated under vacuum. Flash Chromatography (1:1, 
CH2Cl2/Hexanes) gave 3.12 g (31%) of 18 as colourless oil. Rf = 0.35 
(CH2Cl2/Hexanes, 7:3); 
1
H NMR (500 MHz, CDCl3) δ 4.23 (t, 2H, J = 6.5 Hz), 3.29 
(t, 2H, J = 6.7 Hz), 3.00 (s, 3H), 1.81-1.75 (m, 2H), 1.66-1.60 (m, 2H), 1.53-1.47 (m, 
2H); 
13
C NMR (125 MHz, CDCl3) δ 69.5, 51.1, 37.3, 28.7, 28.2, 22.7; HRMS (FAB) 
calcd. for C6H13N3O3NaS (M+Na)
+
: m/e 230.0575, found m/e 230.0568. 
Synthesis of azidoalkyl-1-thioacetates 20-22. General Procedure.  
 To a solution of the corresponding azidoalkylalcohol 17-19 (100 mol%) in DMF 
was added potassium thioacetate (110 mol%) dropwise at room temperature. The 
reaction mixture was stirred overnight, washed with water and extracted tree times 
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with EtOAc. The combined organic phases were washed with saturated NaHCO3 
aqueous solution and brine, dried over anhydrous Na2SO4 and evaporated. The crude 
product was purified by flash chromatography yielding the product. 
4-azidobutyl-1-thioacetate (20).  
 It was prepared following the general procedure from 17 (4.76 g, 24.7 mmol) in 
DMF (70 mL). Purified by column chromatography using EtOAc/Hexanes, 1/9, 
affording 3.58 (84% yield) of 20 as a yellow oil; Rf = 0.65 (EtOAc/Hexanes, 1:9); 
1
H 
NMR (500 MHz, CDCl3) δ 3.35-3.29 (m, 2H), 2.94-2.90 (m, 2H), 2.36 (s, 3H), 1.71-
1.66 (m, 4H); 
13
C NMR (125 MHz, CDCl3) δ 50.9, 30.6, 28.5, 27.9, 26.8. 
5-azidopentyl-1-thioacetate (21).  
 It was prepared following the general procedure from 18 (2.9 g, 14.1 mmol) in 
DMF (100 mL). Purification by column chromatography using hexane: EtOAc, 98:2 
gave 2.32 g (82% yield) of 21 as a yellow oil; Rf = 0.48 (Hexanes/EtOAc, 9:1); 
1
H 
NMR (500 MHz, CDCl3) δ 3.26 (t, 2H, J = 6.5 Hz), 2.87 (t, 2H, J = 6.7 Hz), 2.32 (s, 
3H), 1.62-1.55 (m, 4H), 1.47-1.41 (m, 2H); 
13
C NMR (125 MHz, CDCl3) δ 195.7, 
51.2, 30.6, 29.1, 28.8, 28.4, 25.8; HRMS (FAB) calcd. for C7H14N3OS (M+H)
+
: m/e 
188.0858, found m/e 188.0858. 
6-azidohexyl-1-thioacetate (22).  
 It was prepared following the general procedure from 19 (23.4 g, 105.7 mmol) in 
DMF (250 mL). Purification by column chromatography using hexane: EtOAc gave 
18.07 g (85% yield) of 22 as a yellow oil; Rf = 0.30 (Hexanes/EtOAc, 95:5); 
1
H 
NMR (300 MHz, CDCl3) δ 3.27 (t, 2H, J = 6.8 Hz), 2.86 (t, 2H, J = 7.2 Hz), 2.32 (s, 
3H), 1.66-1.53 (m, 4H), 1.44-1.35 (m, 4H); 
13
C NMR (75 MHz, CDCl3) δ 195.7, 
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51.2, 30.5, 29.3, 28.8, 28.6, 28.1, 26.1; HRMS (FAB) calcd. for C8H15N3ONaS 
(M+Na)
+
: m/e 224.0834, found m/e 224.0831. 
Synthesis of azidoalkanesulfinyl chlorides 23-25. General procedure. 
  To a solution of the adequate thioacetate 20-22 (100 mol%) in methylene 
chloride at -20ºC, acetic anhydride (100 mol%) and sulfuryl chloride ( 200 mol %) 
were added. The resulting mixture was stirred for 1h at -5ºC and then the solvent 
was evaporated and the residue was dried under vacuum to give the corresponding 
sulfinyl chloride, 23-25, that was used without further purification in the following 
reaction for the preparation of sulfinate esters. 
Synthesis of (R)-DAG azidoalkanesulfinates. General procedure.  
 To a solution of 1,2:5,6-Di-O-isopropylidene- -D-glucofuranosyl (DAGOH) (100 
mol %)  and pyridine (300 mol %)) in anhydrous toluene, cooled to -78ºC and placed 
under argon atmosphere, the azidoalkane-1-sulfinyl chloride (200 mol %) was added 
while the reaction mixture was being vigorously stirred. After stirring at -78ºC for 
3h, the reaction mixture was treated with 1M HCl aqueous solution and extracted 
with CH2Cl2. The combined organic layers were successively washed with saturate 
NaHCO3 aqueous solution and brine, dried over Na2SO4 and evaporated, to give the 
R sulfinate as the major diastrereomer. The crude product was purified by clumn 
chromatography obtaining the diastereomerically pure R sulfinate. 
(R)-(1,2:5,6-Di-O-isopropylidene- -D-glucofuranosyl) 4-azidobutanesulfinate 
(10-RS).  
 It was prepared following the general procedure from DAGOH (1.58 g, 6.065 
mmol) and pyridine (1.5 mL) in anhydrous toluene (30 mL), and 4-azidobutyl-1-
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sulfinyl chloride (2.2 g, 12.13 mmol). Diastereomeric ratio: 10R:10S = 77:23. 
Purification by column chrotagraphy,  hexanes /2-propanol, 20:1 , gave 1.73 mg (70 
% yield) of the major diasteromer 10-Rs as yellow oil (90 % of combined yield). Rf = 
0.45 (Hexanes/ 2-propanol, 15:1); [α]D= + 5.6 (c = 1.1, CHCl3); 
1
H NMR (500 MHz, 
C6D6) δ 5.86 (d, 1H, J = 3.5 Hz), 4.93 (d, 1H. J = 3.6 Hz), 4.85 (d, 1H, J = 2.9 Hz), 
4.39 (dd, 1H,  J = 2.9 Hz, J = 8.7 Hz), 4.26-4.22 (m, 1H), 4.07 (dd, 1H, J = 4.6 Hz, J 
= 8.8 Hz), 3.99 (dd, 1H, J = 6.1 Hz, J = 8.8 Hz), 2.52 (t, 2H, J = 6.8 Hz ), 2.42-2.29 
(m, 2H), 1.41-1.35 (m, 2H), 1.34 (s, 3H), 1.33 (s, 3H), 1.22 (s, 3H), 1.06-1.00 (m, 
2H), 0,99 (s, 3H); 
13
C NMR (125 MHz, C6D6) δ 112.7, 109.9, 106.2, 84.8, 83.8, 
81.6, 73.1, 68.2, 57.5, 50.9, 28.2, 27.4, 27.2, 26.4, 25.8, 18.9. HRMS m/e calcd. for 
C16H28N3O7S (M+H)
+
 : 406.1648, found: 406.1654. 
(R)-(1,2:5,6-Di-O-isopropylidene- -D-glucofuranosyl) 5-azidopentanesulfinate 
(26-RS).  
 It was prepared following the general procedure from DAGOH (609 mg, 2.38 
mmol) and pyridine (575 L) in anhydrous toluene (15 mL) and 5-azidopentane-1-
sulfinyl chloride 24 (915 mg, 4.68 mmol). The product was obtained as a 83:17 
mixture of R:S diastereomers. Purification by column chromatography, hexane/2-
propanol (20:1), gave 717 mg (72% yield) of the major diasteromer 26-RS as yellow 
oil, (87 % of combined yield). Rf = 0.40 (Hexanes/ 2-propanol, 10:1); [α]D = - 6.02 
(c = 1.2, CHCl3); 
1
H NMR (500 MHz, C6D6) δ 5.97 (d, 1H, J = 3.5 Hz), 5.05 (d, 1H. 
J = 3.5 Hz), 4.97 (d, 1H, J = 3.0 Hz), 4.50 (dd, 1H,  J = 3.0 Hz, J = 8.5 Hz), 4.38-
4.34 (m, 1H), 4.17 (dd, 1H, J = 4.5 Hz, J = 8.5 Hz), 4.10 (dd, 1H, J = 6.0 Hz, J = 8.5 
Hz), 2.67 (t, 2H, J = 6.5 Hz), 2.58-2.44 (m, 2H), 1.50-1.45 (m, 2H), 1.45 (s, 3H), 
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1.44 (s, 3H), 1.33 (s, 3H), 1.11-1.03 (m, 2H), 1,09 (s, 3H), 1.05-0.95 (m, 2H); 
13
C 
NMR (125 MHz, C6D6) δ 112.3, 109.6, 105.9, 84.5, 83.5, 81.3, 72.8, 67.9, 57.7, 
50.9, 28.5, 27.1, 26.9, 26.1, 25.9, 25.5, 20.8; HRMS (FAB) calcd. for 
C17H29N3O7NaS (M+Na)
+
: m/e 442.1624, found m/e 442.1630. 
(R)-(1,2:5,6-Di-O-isopropylidene- -D-glucofuranosyl) 6-azidohexanesulfinate 
(27-RS). 
  It was prepared following the general procedure from DAGOH (7.86 g, 30.2 
mmol) and pyridine (8.8 mL) in anhydrous toluene (60 mL), and 6-azidohexane-1-
sulfinyl chloride (36 mmol). The product was obtained as a 82:18 mixture of R:S 
diastereomers. Purification by column chromatography, hexane/2-propanol (20:1), 
gave 9.25 g (71 % yield) of the major diasteromer 27-RS as yellow oil (86 % of 
combined yield). Rf = 0.26 (Hexanes/ 2-propanol, 10:1); [α]D = - 5.2 (c = 1.0, 
CHCl3); 
1
H NMR (300 MHz, CDCl3) δ 5.90 (d, 1H, J = 3.6 Hz), 4.77 (d, 1H, J = 3.9 
Hz), 4.71 (d, 1H, J = 1.9 Hz), 4.16-4.08 (m, 3H), 4.03-3.97 (m, 1H), 3,27 (t, 2H, J = 
6.74 Hz), 2.91-2.71 (m, 2H), 1.81-1.70 (m, 2H), 1.66-1.55 (m, 2H), 1.49 (s, 3H), 
1.48-1.42 (m, 4H), 1.42 (s, 3H), 1.32 (s, 3H), 1,29 (s, 3H, CH3); 
13
C NMR (75 MHz, 
CDCl3) δ 112.4, 109.4, 105.3, 83.8, 83.0, 80.9, 72.2, 67.7, 57.6, 51.3, 28.6, 28.3, 
26.8, 26.7, 26.4, 26.2, 25.3, 20.9; HRMS (FAB) calcd. for C18H32N3O7S (M+H)
+
: 
m/e 434.1961, found m/e 434.1950. 
Synthesis of (S)-DAG azidoalkanesulfinates. General procedure. 
  To a solution of 1,2:5,6-Di-O-isopropylidene- -D-glucofuranosyl (DAGOH) 
(100 mol %) and N,N-diisopropylehtylamine (300 mol %) in anhydrous toluene, 
cooled to -78ºC and placed under argon atmosphere, the azidobutyl-1-sulfinyl 
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chloride (200 mol %) was added while the reaction mixture was being vigorously 
stirred. After stirring at -78ºC for 3h, the reaction mixture was treated with HCl 1M 
and extracted with CH2Cl2. The combined organic layers were successively washed 
with saturate NaHCO3 aqueous solution and brine, dried over Na2SO4 and evaporated 
to give the corresponding sulfinate as a mixture of diastereomers, with the S isomer 
as the major one. The crude product was purified by silica gel chromatography to 
give the optically pure S sulfinate  
(S)-(1,2:5,6-Di-O-isopropylidene- -D-glucofuranosyl) 4-azidobutanesulfinate 
(10-Ss). 
  Prepared following the general procedure from DAGOH (1.12 g, 4.3 mmol) and 
N,N-diisopropylehtylamine (2.25 mL) in anhydrous toluene (20 mL) and 4-
azidobutyl-1-sulfinyl chloride 23 (1.56 g, 8.6 mmol). Diastereomeric ratio 10S:10R= 
92:8. Purification by column chromatography, hexane /2-propanol, 20:1,  to give 
1.52 g (87 % yield) of the major diasteromer 10-SS as yellow oil ( 91.5 % of 
combined yield). Rf = 0.40 (Hexanes/ 2-propanol, 15:1); [α]D= - 55.2 (c = 1.2, 
CHCl3); 
1
H NMR (500 MHz, C6D6) δ 5.82 (d, 1H, J = 3.6 Hz), 4.83 (d, 1H, J = 2.7 
Hz), 4.50 (d, 1H , J = 3.6 Hz), 4.47 (dd, 1H , J = 7.2 Hz, J = 2.7 Hz),  4.45-4.41 (m, 
1H), 4.15 (dd, 1H,  J = 8.5 Hz, J = 5.2 Hz), 4.09 (dd, 1H, J = 8.4 Hz, J = 6. 1 Hz), 
2,51 (t, 2H, J = 6.75 Hz),  2.22 (t, 2H,  J = 7.8 Hz), 1.40 ( s, 3H), 1.35 (s, 3H), 1.34-
1.25 (m, 2H), 1.30 (s, 3H), 1.06 (s, 3H), 1.05-0.97 (m, 2H); 
13
C NMR (125 MHz, 
CDCl3) δ 112.7, 109.8, 105.9, 84.6, 81.3, 79.5, 73.3, 67.6, 56.8, 50.9, 28.3, 27.4, 
27.2, 26.6, 25.8, 19.0.  
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(S)-(1,2:5,6-Di-O-isopropylidene- -D-glucofuranosyl) 5-azidopentanesulfinate 
(26-SS). 
  Prepared following the general procedure from DAGOH (605 mg, 2.32 mmol) 
and N,N-diisopropylehtylamine (1.2 mL) in anhydrous toluene (15 mL) and 5-
azidopentane-1-sulfinyl chloride 24 (910 mg, 4.64 mmol). The sulfinate was 
obtaines as a 94:6 (24S: 24R) mixture of diastereomers. Purification by column 
chromatography, hexane / 2-propanol, 20:1, gave 870 mg (89.3 % yield) of the 
major diasteromer 26-SS as yellow oil (92 % of combined yield). Rf = 0.42 ( 
Hexanes/ 2-propanol, 10:1); [α]D= - 49.95 (c = 1.0, CHCl3); 
1
H NMR (500 MHz, 
C6D6) δ 5.82 (d, 1H, J = 3.5 Hz), 4.85 (d, 1H, J = 2.5 Hz), 4.51 (d, 1H , J = 3.5 Hz), 
4.49-4.43 (m, 2H), 4.16 (dd, 1H, J = 8.5 Hz, J = 5.5 Hz), 4.10 (dd, 1H, J = 8.5 Hz, J 
= 6.0 Hz), 2,57 (t, 2H, J = 6.5 Hz), 2,29 (t, 2H, J = 7.5 Hz), 1.41 (s, 3H), 1.35 (s, 
3H), 1.34-1.26 (m, 2H), 1.29 (s, 3H), 1.07 (s, 3H), 1.00-0.96 (m, 2H), 0.93-0.87 (m, 
2H); 
13
C NMR (125 MHz, C6D6) δ 112.4, 109.5, 105.6, 84.3, 81.0, 79.1, 73.0, 67.3, 
57.0, 50.9, 28.5, 27.0, 26.9, 26.3, 25.9, 25.5, 20.9; HRMS (FAB) calcd. for 
C17H29N3O7NaS (M+Na)
+
: m/e 442.1624, found m/e 442.1630. 
 (S)-(1,2:5,6-Di-O-isopropylidene- -D-glucofuranosyl) 6-azidohexanesulfinate 
(27-SS).  
 Prepared following the general procedure from DAGOH (7.32 g, 28 mmol) and 
N,N-diisopropylehtylamine (15 mL) in anhydrous toluene  and 6-azidohexane-1-
sulfinyl chloride 25 (33.7 mmol). The product was obtained as a 92:8 mixture of S:R 
diastereomers . Purification by column chromatography,  hexane/2-propanol (20:1), 
gave 9.53 g (78.4 % yield) of the major diastereoisomer 27-SS as yellow oil  (85.2% 
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of combined yield). Rf = 0.25 (Hexanes/ 2-propanol, 10:1); [α]D= - 39.3 (c = 1.0, 
CHCl3); 
1
H NMR (300 MHz, CDCl3) δ 5.90 (d, 1H, J = 3.6 Hz), 4.74 (d, 1H, J = 2.5 
Hz), 4.60 (d, 1H , J = 3.70 Hz), 4.32-4.24 (m, 2H), 4.09 (dd, 1H, J = 8.5 Hz, J = 5.8 
Hz), 4.01 (dd, 1H, J = 8.5 Hz, J = 5.0 Hz), 3,27 (t, 2H, J = 6.74 Hz), 2.88-2.70 (m, 
2H), 1.78-1.67 (m, 2H), 1.66-1.56 (m, 2H), 1.51 (s, 3H), 1.44-1.36 (m, 4H), 1.43 (s, 
3H),  1.34 (s, 3H), 1.31 (s, 3H); 
13
C NMR (75 MHz, CDCl3) δ 112.4, 109.2, 104.9, 
83.6, 80.3, 79.2, 72.3, 66.7, 57.1, 51.2, 28.5, 28.3, 26.7, 26.7, 26.3, 26.2, 25.2, 21.1; 
HRMS (FAB) calcd. for C18H31N3O7NaS (M+Na)
+
: m/e 456.1780, found m/e 
456.1780. 
Synthesis of (S)- and (R)-azidoalkyl sulfoxides. General procedure.  
 To a solution of the (R)- or (S)-DAG azidoalkanesulfinate ester  (100 mol%) in 
anhydrous toluene, at 0ºC,  the adequate alkyl magnesium bromide solution (150 
mol %) was added. After stirring for 1h at 0ºC, saturated NH4Cl aqueous solution 
was added. The aqueous layer was extracted with CH2Cl2 and the resulting organic 
layers were combined, dried on Na2SO4, and concentrated. The crude product was 
purified by silica gel chromatography. 
 (S)-(-)-1-Azido-4-(methylsulfinyl)-butane (28-SS).  
 Prepared following the general procedure from sulfinate ester 10-RS (1.41 g, 3.48 
mmol) in anhydrous toluene (20 mL), and  methyl magnesium bromide 1.4M (3.75 
ml, 5.22 mmol). Purification by column chromatography EtOC/MeOH (9:1) gave 
486 mg (87% yield) of the compound 27-SS as a colourless liquid. Rf = 0.31 (EtOAc 
/ MeOH, 9:1); [α]D  = + 86,33 (c = 1.1, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 3.34 
(dt, 2H, J = 2.0 Hz, J = 6.6 Hz), 2.76-2.64 (m, 2H), 2.56 (s, 3H), 1.89-1.83 (m, 2H), 
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1.81-1.68 (m, 2H); 
13
C NMR (125 MHz, CDCl3) δ 53.8, 50.8, 38.4, 28.0, 20.0; 
HRMS m/e calcd. for C5H12N3OS (M+H)
+
 : 162.0701, found: 162.0699. 
(R)-(-)-1-Azido-5-(methylsulfinyl)-pentane (29-RS). 
  Prepared following the general procedure from sulfinate ester 26-SS (440 mg, 
1.05 mmol) in anhydrous toluene (10 mL), and methyl magnesium bromide 1.4M 
(1.12 ml, 1.57 mmol).  Purification by column chromatography, EtOAc/ MeOH 
(9:1), to give   135 mg (74% yield) of sulfoxide 29-RS as a colourless liquid. Rf = 
0.16 (EtOAc / MeOH, 9:1); [α]D  = - 60,42 (c = 1.6, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ 3.29 (t, 2H, J = 6.5 Hz), 2.79-2.73 (m, 1H), 2.69-2.63 (m, 1H), 2.58 (s, 
3H), 1.84-1.77 (m, 2H), 1.67-1.59 (m, 2H), 1.57-1.48 (m, 2H); 
13
C NMR (75 MHz, 
CDCl3) δ 54.2, 51.0, 38.4, 28.5, 25.9, 22.2; HRMS (FAB) m/e calcd. for 
C6H13N3ONaS (M+Na)
+
: 198.0677, found: 198.0680. 
(S)-(-)-1-Azido-5-(methylsulfinyl)-pentane (29-SS).  
 Prepared following the general procedure from sulfinate ester 26-RS (387 mg, 
0.92 mmol)  in anhydrous toluene (15 mL), and  methyl magnesium bromide 1.4M 
(1.0 ml, 1.38 mmol).  Purification by column chromatography, EtOAc/ MeOH (9:1) 
gave 125 mg (78% yield) of sulfoxide 29-SS as a yellow liquid, with identical 
spectroscopic characteristics than the 29-RS enantiomer. [α]D  = + 61.25 (c = 0.8, 
CHCl3); HRMS (FAB) m/e calcd. for C6H13N3ONaS (M+Na)
+
: 198.0677, found: 
198.0670. 
(R)-(-)-1-Azido-6-(methylsulfinyl)-hexane (30-RS). 
  Prepared following the general procedure from sulfinate 26-SS (2.89 g, 6.66 
mmol) in anhydrous toluene (15 mL), and  methyl magnesium bromide 1.4M (7.2 
ml, 10 mmol).  Purification by column chromatography, EtOAc/ MeOH (9:1) gave 
33 
 
926 mg (73% yield) of sulfoxide 30-RS as a colourless liquid. Rf = 0.17 (EtOAc / 
MeOH, 9:1); [α]D  = - 64,24 (c = 1.1, CHCl3); 
1
H NMR (300 MHz, CDCl3) δ 3.26 (t, 
2H, J = 6.9 Hz), 2.77-2.58 (m, 2H), 2.54 (s, 3H), 1.82-1.72 (m, 2H), 1.65-1.36 (m, 
6H); 
13
C NMR (75 MHz, CDCl3) δ 54.5, 51.2, 38.6, 28.5, 28.3, 26.3, 22.4; HRMS 
(FAB) m/e calcd. for C7H16N3OS (M+H)
+
: 190.1014, found: 190.1021. 
(S)-(-)-1-Azido-6-(methylsulfinyl)-hexane (30-SS). 
  Prepared following the general procedure from sulfinate ester 27-RS (2.55 g, 5.87 
mmol)   in anhydrous toluene (50 mL), and  methyl magnesium bromide 1.4M (6.3 
ml, 8.8 mmol).  Purification by column chromatography, EtOAc/ MeOH (9:1) gave 
895 mg (81% yield) of sulfoxide 30-SS as a colourless liquid, with identical 
spectroscopic characteristics than the 30-RS enantiomer. [α]D = + 61,00 (c = 0.6, 
CHCl3); HRMS (FAB) m/e calcd. for C7H15N3ONaS (M+Na)
+
: 212.0834, found: 
212.0836. 
(R)-(-)-1-Azido-4-(ethylsulfinyl)-butane (31-RS).  
 Prepared following the general procedure from sulfinate ester 10-SS (320 mg, 0.78 
mmol) in anhydrous toluene (10 mL), and  ethyl magnesium bromide 1.0 M (1.2 ml, 
1.2 mmol). Purification by column chromatography, EtOAc/ MeOH (9:1) gave 122 
mg (90% yield) of sulfoxide 31-RS as a colourless liquid. Rf = 0.35 (EtOAc / MeOH, 
9:1); 
1
H NMR (500 MHz, CDCl3) δ 3.34 (dt, 2H, J1 = 1.8 Hz, J2 = 6.5 Hz), 2.76-2.69 
(m, 3H), 2.68-2.612 (m, 2H), 1.92-1.83 (m, 2H), 1.82-1.69 (m, 2H), 1.33 (t, 3H, J = 
7.5 Hz); 
13
C NMR (125 MHz, CDCl3) δ 50.9, 50.8, 45.6, 28.0, 20.1, 6.8; HRMS m/e 
calcd. for C6H14N3OS (M+H)
+
: 176.0858, found: 176.0863. 
(R)-(-)-1-Azido-4-(butylsulfinyl)-butane (32-RS).  
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 Prepared following the general procedure from sulfinate ester 10-SS (334 mg, 0.82 
mmol) in anhydrous toluene (50 mL), and  butyl magnesium bromide 2.0 M (0.6 ml, 
1.23 mmol). Purification by column chromatography, EtOAc/ MeOH (9:1) gave 158 
mg (95% yield) of sulfoxide 32-RS as a colourless liquid. Rf = 0.68 (EtOAc / MeOH, 
9:1); [α]D  = - 9,18 (c = 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 3.35 (dt, 2H, J = 
2.2 Hz, J = 6.6 Hz), 2.79-2.72 (m, 2H), 2.70-2.62 (m, 2H), 1.92-1.86 (m, 2H), 1.82-
1.70 (m, 4H), 1.55-1.42 (m, 2H), 0.96 (t, 3H, J = 7.4 Hz); 
13
C NMR (125 MHz, 
CDCl3) δ 52.1, 51.5, 50.9, 28.0, 24.6, 22.0, 20.1, 13.6; HRMS m/e calcd. for 
C8H18N3OS (M+H)
+
: 204.1171, found: 204.1165. 
Synthesis of (R)- and (S)-isothiocyanates. General Procedure.  
 To a solution of the corresponding azide derivative,  28-32, (100 mol %) in Et2O 
was added triphenylphosphine (190 mol %), and  the reaction was refluxed for 1h.. 
After  removing the solvent at vacuum, carbon disulfide was added and the mixture 
was refluxed for 3h. Finally the solvent was removed under vacuum and the crude 
product was purified by silica gel chromatography. 
(-)-(R)-1-isothiocyanate-4-(butylsulfinyl)-butane (2-RS).  
 It was prepared following the general procedure from the azide 28-RS (140 mg, 
0.69 mmol) in Et2O (5mL), triphenylphosphine (343 mg, 1.31 mmol), and carbon 
disulfide (3 mL). ; Purification by column chromatography,  EtOAc/ MeOH (9:1), 
affording 149 mg (98% yield ) of 2R as colourless liquid. Rf = 0.15 (EtOAc / MeOH, 
9:1); [α]D = -80.81 (c = 1.0 , CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 3.59 (t, 2H, J = 
6.0Hz), 2.76-2.62 (m, 4H), 1.98-1.82 (m, 4H), 1.79-1.72 (m, 2H), 1.56-1.43 (m, 2H), 
0.98 (t, 3H, J = 7.3 Hz); 
13
C NMR (125 MHz, CDCl3) δ 52.4, 51.3, 44.7, 29.1, 24.6, 
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22.1, 20.2, 13.7; HRMS m/e calcd. for C9H17NONaS2 (M+Na)
+
 : 242.0649, found: 
242.0654. 
(+)-(S)-1-isothiocyanate-4-(methylsulfinyl)-butane (2-SS).  
 It was prepared following the general procedure fron azide 28-Ss (248 mg, 1.55 
mmol) in Et2O (15 mL), triphenylphosphine (770 mg, 2.93 mmol), and carbon 
disulfide (5 mL). Purification by column chromatography, EtOAc/ MeOH (9:1), 
gave 215 mg (78 % yield) of 2SS, as a colourless liquid. Rf = 0.30 (EtOAc / MeOH, 
9:1); [α]D = + 80.00 (c = 0.8, CHCl3); Spectroscopical data identical to those of the 2-
RS enantiomer. HRMS m/e calcd. for C6H12NOS2 (M+H)
+
: 178.0360, found: 
178.0358.  
(-)-(R)-1-isothiocyanate-5-(methylsulfinyl)-pentane (4-RS). 
  It was prepared following the general procedure from  the azide derivative 29-RS 
(115 mg, 0.66 mmol),  triphenylphosphine (327 mg, 1.25 mmol) in anhydrous Et2O 
(3 mL), and carbon disulfide (1 mL). Purification by column chromatography, 
EtOAc/ MeOH (9:1), gave 106 mg (91% yield) of 4-RS, as an ambar syrup. Rf = 0.25 
(EtOAc / MeOH, 9:1); [α]D = - 73.48 (c = 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 
3.54 (t, 2H, J = 6.5 Hz), 2.76-2.63 (m, 2H), 2.57 (s, 3H), 1.86-1.73 (m, 4H), 1.67-
1.55 (m, 2H); 
13
C NMR (125 MHz, CDCl3) δ 54.2, 44.7, 38.7, 29.6, 25.8, 21.9; 
HRMS m/e calcd. for C7H13NONaS2 (M+Na)
+
: 214.0336, found: 214.0339.  
(+)-(S)-1-isothiocyanate-5-(methylsulfinyl)-pentane (4-SS).  
 It was prepared following the general procedure from the azide derivative 28-SS 
(99.6 mg, 0.57 mmol), triphenylphosphine (283 mg, 1.08 mmol) in anhydrous Et2O 
(3 mL) and carbon disulfide (1 mL). Purification by column chromatography, 
EtOAc/ MeOH (9:1), gave 106 mg (97% yield) of 4-SS, as anambar syrup. The 
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spectroscopic data are identical to those of its enantiomer, 4-RS. [α]D = + 69.23 (c = 
0.8, CHCl3); HRMS m/e calcd. for C7H14NOS2 (M+H)
+
: 192.0517, found: 
192.0515. 
(R)-(-)-1-isothiocyanato-6-(methylsulfinyl)hexane (5-RS). 
  It was prepared following the general procedure fro the azide derivative 30-RS 
(816 mg, 4.32 mmol), triphenylphosphine (2.15 g, 8.2 mmol) in anhydrous Et2O (3 
mL) and carbon disulfide (6.5 mL). Purification by column chromatography, EtOAc/ 
MeOH (9:1), gave 710 mg (81% yield) of 5-RS, as an ambar syrup. Rf = 0.4 (EtOAc 
/ MeOH, 9:1); [α]D = - 70.62 (c = 0.5, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 3.52 (t, 
2H, J = 10.5 Hz), 2.77-2.60 (m, 2H), 2.56 (s, 3H), 1.83-1.67 (m, 4H), 1.53-1.46 (m, 
4H); 
13
C NMR (125 MHz, CDCl3) δ 54.4, 44.9, 38.7, 29.6, 27.9, 26.2, 22.4; HRMS 
m/e calcd. for C8H16NOS2 (M+H)
+
: 206.0673, found: 206.0669.  
(+)-(S)-1-isothiocyanate-6-(methylsulfinyl)-hexane (5-SS). 
  It was prepared following the general procedure, from the azido derivative 30-SS 
(870 mg, 4.6 mmol),  triphenylphosphine (2.3 g, 8.75 mmol) in anhydrous Et2O (3 
mL), and carbon disulfide (7 mL). Purification by column chromatography, EtOAc/ 
MeOH (9:1), gave 820 mg (87% yield) of 5-SS, as an ambar syrup. The 
spectroscopic data are identical to those of its enantiomer, 5-RS. [α]D = + 68.77 (c = 
1.0, CHCl3); HRMS m/e calcd. for C8H16NOS2 (M+H)
+
: 206.0673, found: 
206.0677. 
(R)-(-)1-isothiocyanato-4-(ethylsulfinyl)-butane (6-RS).  
 It was prepared following the general procedure from the azide derivative 31-Rs 
(90 mg, 0.51 mmol) in Et2O (4 mL), triphenylphosphine (261 mg, 0.99 mmol), and 
carbon disulfide (1 mL). Purification by column chromatography, EtOAc/ MeOH 
37 
 
(9:1), gave 92 mg (95% yield) of 6-RS as a yellow liquid. Rf = 0.20 (EtOAc / MeOH, 
9:1); 
1
H NMR (500 MHz, CDCl3) δ 3.59 (t, 2H, J = 5.9Hz), 2.78-2.70 (m, 3H), 2.70-
2.63 (m, 1H), 1.99-1.82 (m, 4H), 1.35 (t, 3H, J = 7.5 Hz); 
13
C NMR (125 MHz, 
CDCl3) δ 50.6, 46.0, 44.7, 29.1, 20.2, 6.8; HRMS m/e calcd. for C7H13NONaS2 
(M+Na)
+
 : 214.0336, found: 214.0338. 
(-)-(R)-1-isothiocyanato-4-(butylsulfinyl)-butane (7-RS).   
 It was prepared following the general procedure from the azide derivative 32-RS 
(140 mg, 0.69 mmol) in Et2O (5 mL), triphenylphosphine (343 mg, 1.31 mmol), and 
carbon disulfide (3 mL). Purification by column chromatography, EtOAc/MeOH 
(9:1), gave 149 mg (98% yield) of 7-RS as a colourless liquid. Rf = 0.15 (EtOAc / 
MeOH, 9:1); [α]D = -8.81 (c = 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ 3.59 (t, 
2H, J = 6.0Hz), 2.76-2.62 (m, 4H), 1.98-1.82 (m, 4H,), 1.79-1.72 (m, 2H), 1.56-1.43 
(m, 2H), 0.98 (t, 3H, J = 7.3 Hz); 
13
C NMR (125 MHz, CDCl3) δ 52.4, 51.3, 44.7, 
29.1, 24.6, 22.1, 20.2, 13.7; HRMS m/e calcd. for C9H17NONaS2 (M+Na)
+
 : 
242.0649, found: 242.0654. 
4.2. Biological activity of sulforaphane and sulforaphane analogues 
4.2.1. ACTIVATION OF NRF2 
- Construction of a rNQO1-ARE luciferase reporter plasmid 
The rat NQO1-ARE luciferase reporter plasmid (pGL3-rNQO1 ARE) has previously 
been described [63].   
- Transient transfection and luciferase reporter assays. 
HaCaT cells (human immortalized keratinocyte cell line) were cultured in DMEM 
medium containing 10% fetal calf serum (FCS) and 1% Penicillin/Streptomycin. 
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Transfection was performed with linear polyethylenimine (Polysciences). HaCaT 
cells were plated at a density of 2 x 10
5
 cells/well in 12-well plates (Nunc) in 1ml 
DMEM, 10% FCS, 1% Penicillin/Streptomycin and grown until 80% (24h). Cells 
were washed twice with PBS, placed in 1ml Opti-MEM I (GIBCO) and co-
transfected with 2µg of the rNQO1-ARE luciferase reporter plasmid and 0.01µg of 
the phRL-CMV Renilla luciferase vector plasmid (Promega) as an internal control 
for transfection efficiency. Both plasmid DNAs were diluted with 106µl 0.9% (w/v) 
sodium chloride solution. 3.8µl of polyethylenimine solution (1mg/ml) was then 
added and briefly vortexed. The mixture was incubated at room temperature for 
15min to allow complex formation. Afterwards the transfection mix was added to 
the cells. After 4h the transfection mix was fully replaced by fresh cell culture 
medium (DMEM, 10% FCS, 1% Penicillin/Streptomycin). After 24h the cells were 
washed with PBS and incubated with fresh culture medium containing different 
concentrations of the sulforaphane homologues (50nm, 0.5µM, 5µM, 50µM, 
500µM) or DMSO as negative control. Cells were harvested 20h later using Passive 
Lysis Buffer (Promega). The firefly and renilla luciferase activities were measured 
in the supernatants using the Dual-Luciferase Reporter Assay System kit from 
Promega according to the manufacture’s instructions. Luciferase activity was 
determined on a MicroLumatPlus LB96V (EG&G Berthold) and reported as x-fold 
activation compared to DMSO-treated cells. Results show mean plus/minus S.D. 
from triplicate determinations. 
 
4.2.2. CYTOTOXIC ACTIVITY 
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All cell lines used (A-549, MRC5) were obtained from the European collection of 
cell cultures (European Collection of Cell Cultures). Both were cultured in DMEM 
(Dulbecco's Modified Eagle's Medium ) supplemented with 2 mM glutamine, 50 g 
/ mL of both penicillin and streptomycin and 10% fetal bovine serum (FBS) and 
have been incubated in an atmosphere of air at 95 % humidity, 5% CO2 and 37 °C. 
The cellular proliferation/viability was assessed by the MTT (3 – [4,5 - 
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. The MRC-5 cell line 
has been cultivated at 9x10
3
 cells / well, while A-459 cells were cultivated at 4.5 
x10
3
 cellsd/ well, in a 96 well plate for 24h. After this time, sulforaphane and 
sulforaphane homologues were added to the wells. After 48h the cell medium was 
removed and 125 l of MTT (1 mg / ml in medium) was added and allowed to react 
for 4h. Then, 80 l of a 20 % SDS solution in hydrochloric acid (0.002M) was added 
and the mixture and incubated for 10h at 37 °C. The cell viability was quantified by 
optical density at 540nm using a multi-well plate reader spectrophotometer. The 
results are expressed as the percentage of cell viability relative to controls. All data 
are the result of at least three independent experiments; the results of statistical 
analysis (p value) for the t-test are also indicated. 
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Figure 1: Structure of sulforaphane and homologues synthesized in this work. 
 
 
 
Figure 2: Diastereomeric intermediates used for the synthesis of enantiopure and scalemic 
RS-sulforaphane. 
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Figure 3: Dose dependent effects of sulforaphane analogues on the activation of an ARE 
reporter gene. HaCaT keratinocytes were transiently transfected with the rNQO1-ARE 
luciferase reporter plasmid and the phRL-CMV Renilla luciferase vector. Transfected cells 
were incubated for 24h with different concentrations of the sulforaphane 2-RS and 
homologues 4-RS, 4-SS 5-RS, 5-SS, 6-RS, and 7-RS. Results were normalized to the renilla 
luciferase activity. Values show mean +/- S.D. from triplicate determinations.  The result 
was reproduced in an independent transfection experiment. 
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Figure 4. Inverted microscope images corresponding MRC-5 and A549 cell lines following 
treatment with 5-SS analogue at a 10 M concentration . 
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Scheme 1: Biosynthetic pathway to (RS)-sulforaphane 2 and (RS, SC)-sulforaphane-
cysteine analogue 3: Lossen rearrangement through myrosinase deglycosylation of 
glycopharin 1 followed by mercapturic acid pathway. 
 
 
 
 
Scheme 2: Synthesis of 1-azido-butanesulfinyl chlorides 23-25. a) NaN3, DMF, b) MsCl, 
NEt3, CH2Cl2, c) KSAc, DMF, d) SO2Cl2, Ac2O, CH2Cl2 
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Scheme 3: Enantiodivergent synthesis of (S)- and (R)-sulfinate esters 10, 26, and  27 
using the DAG-methodology 
 
 
 
Scheme 4: Synthesis of enantiopure natural sulforaphane 2-RS and homologues 4-RS and 
5-RS: a) CH3MgBr, toluene b) (i) PPh3, Et2O, reflux, (ii) CS2, reflux. 
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Scheme 5: Synthesis of enantiopure unnatural sulforaphane 2-SS and homologues 4-SS 
and 5-SS: a) CH3MgBr, toluene b) (i) PPh3, Et2O, reflux, (ii) CS2, reflux. 
 
 
 
Scheme 6: Synthesis of enantiopure sulforaphane analogues 6-RS and 7-RS: a) 
C2H5MgBr, toluene b) C4H7MgBr, toluene, c) (i) PPh3, Et2O, reflux, (ii) CS2, reflux. 
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Table 1. Selective cytotoxic effect of sulforaphane analogues on tumoral (A549) and 
normal (MRC-5) cells.
 
Entry Compound 
 
A549 
IC50 ( M) 
 
 
MRC-5 
IC50 ( M) 
 
 
P 
1 lactic acid 26.61
a
  23.93
a
  0.1811 
2 Cisplatin 11,67 115,71  
3 2-RS 19.60 46.58 0.0090 
4 4-RS 9.62 18.54 0.0050 
5 4-SS 12.00
 
20.25 0.0100 
6 5-RS 10.06
 
16.92 0.0390 
7 5-SS 7.54 17.58 0.0030 
8 6-RS 19.78 40.79 0.0020 
9 7-RS 9.77 17.44 0.0001 
 
a
IC50 (mM) 
 
